This Multibagger Healthcare Stock Rises 550% in 1 Year: What Is Behind the Surge?

This multibagger healthcare stock has turned Rs 1 lakh into roughly Rs 6.5 lakh in just one year. A sexual wellness and contraceptive manufacturer ranked second among 101 NSE stocks in our screen with a 1-year return of 550.05%, as of 10 September 2026.

The company is Cupid Ltd (NSE: CUPID), a Nashik-based maker of male and female condoms, lubricants and diagnostic kits that now also sells perfumes, deodorants and personal care products. The Cupid share price traded around Rs 281.40 on 10 September 2026, up about 0.6% on the day, giving the company a market value of approximately Rs 37,597 crore.

Click Here – Get Free Investment Predictions

Which Multibagger Healthcare Stock Rose 550% in 1 Year?

The answer is Cupid. The multibagger healthcare stock climbed from a bonus-adjusted level of roughly Rs 43 a year ago to around Rs 281 today. It touched a record high of Rs 299 in August 2026, while its 52-week low stands at Rs 37.46.

The table below shows how the stock has performed across periods and where it ranks among the 101 stocks in our screen. All figures are adjusted for corporate actions.

Period	Return	Rank (out of 101)
1 Month	0.21%	95
6 Months	227.82%	3
1 Year	550.05%	2
3 Years	6,701.93%	1
5 Years	12,196.94%	1

The 1-month number shows the rally has paused. The stock has been consolidating between Rs 265 and Rs 300 since mid-August, after a near straight-line run from April to August 2026. Few names in our screen match this multibagger healthcare stock on consistency, with a top-three rank in the 6-month, 1-year, 3-year and 5-year windows.

Is the 550% Rise Real or a Bonus Share Effect?

The rise is real price appreciation. Cupid issued 4:1 bonus shares with a record date of 9 March 2026, so the unadjusted price fell from above Rs 400 to around Rs 80 on the ex-date. Our return figures compare bonus-adjusted prices, so the bonus does not inflate them.

The company also split its shares from a face value of Rs 10 to Re 1 and issued 1:1 bonus shares in April 2024. These actions explain why the 3-year and 5-year returns look extreme. Even after full adjustment, the multibagger healthcare stock has multiplied roughly 68 times in three years, a sign of a real business re-rating rather than an accounting quirk. For anyone comparing the multibagger healthcare stock with peers, adjusted prices are the fair yardstick.

Why Did This Multibagger Healthcare Stock Rise 550%?

Four forces drove the rally: rapid earnings growth, repeated upgrades to management guidance, new capacity and a push into consumer products. Each one fed the next, and the market rewarded the multibagger healthcare stock with a steep rise in valuation.

1. Profits Nearly Tripled in a Year

Cupid posted Q1 FY27 revenue of Rs 156.99 crore, up about 142% from Rs 64.74 crore a year earlier. Net profit rose approximately 194% to Rs 44.15 crore from Rs 15.01 crore. For the full year FY26, revenue almost doubled to Rs 391.40 crore and net profit jumped to Rs 108.23 crore from Rs 40.89 crore.

Revenue has now grown for five straight quarters. This consistency matters because it shows the multibagger healthcare stock is not riding on a single large order. That earnings trajectory is the core reason the multibagger healthcare stock re-rated so quickly.

2. Guidance Raised Again and Again

Management first guided for FY26 revenue of about Rs 335 crore and delivered Rs 391.40 crore. In July 2026, it lifted the FY27 revenue target from Rs 600 crore to more than Rs 660 crore. After the Q1 results in August, it raised the goal again to Rs 725 crore to Rs 750 crore, with net profit guidance of Rs 210 crore to Rs 225 crore.

Each upgrade triggered a fresh leg higher in the Cupid share price. Investors now track the company's longer-term aim of around Rs 1,500 crore in revenue by FY29. For a multibagger healthcare stock, guidance that is beaten rather than missed builds trust quickly.

3. Global Tender Wins and Export Price Hikes

Cupid is prequalified by the WHO and UNFPA for both male and female condoms, which makes it eligible for large public health tenders. It received an allocation under a South African condom programme in November 2025 and signed a long-term supply agreement with a Netherlands-based global health supply chain body.

Exports made up approximately 59% of FY26 revenue, with products sold in more than 125 countries. The company also pushed through a minimum 10% price increase across its export portfolio, which supports margins. Tender visibility gives the multibagger healthcare stock a steady institutional revenue base alongside its consumer brands.

4. New Capacity and a Consumer Products Push

A new facility at Palava is expected to take annual capacity to about 1.25 billion male condoms and 125 million female condoms, with commissioning planned in Q2 FY27. The board has also approved plans for a manufacturing venture in South Africa and an FMCG unit in Saudi Arabia.

On the consumer side, the Consumer Healthcare and FMCG portfolio contributed Rs 121.61 crore in FY26, including Rs 84.26 crore from newly launched products. This diversification gives the multibagger healthcare stock a second growth engine beyond institutional tenders.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

How Does This Multibagger Healthcare Stock Compare With Its Sector?

Cupid operates in a niche corner of healthcare. The global market for public health condom supply is served by a small group of WHO-prequalified manufacturers, and Cupid is one of the few that is approved for both male and female condoms. That qualification is hard to win and takes years to build.

The company also says it is the only Indian manufacturer with dedicated natural latex and premium nitrile production lines. This gives the multibagger healthcare stock an edge in premium and specialised products that carry better pricing.

The contrast with the wider sector shows up in valuation. The industry PE is approximately 35.58, while Cupid trades at more than seven times that level. The market is treating the multibagger healthcare stock as a high-growth consumer and export story rather than a traditional contract manufacturer, and that view will be tested with every quarterly result.

Financial Performance of the Multibagger Healthcare Stock

Margins have widened alongside revenue. The operating margin rose from 35.82% in Q1 FY26 to 40.29% in Q1 FY27, and the full-year FY26 operating margin reached 42.06% against 33.45% in FY25.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Operating Margin
Jun 2025	64.74	21.41	15.01	35.82%
Sep 2025	90.23	34.19	24.13	40.50%
Dec 2025	104.39	45.19	32.83	48.33%
Mar 2026	132.04	49.59	36.26	41.35%
Jun 2026	156.99	62.32	44.15	40.29%

The balance sheet is clean. Debt to equity stands at approximately 0.13, and return on equity is about 24%. Operating cash flow turned positive at Rs 46.12 crore in FY26 after a negative Rs 11.14 crore in FY25. A multibagger healthcare stock with rising margins and little debt is rarer than one with rising sales alone.

Who Owns This Multibagger Healthcare Stock?

Promoters have steadily raised their stake, while foreign investors have started to show up. Domestic institutions still hold very little, which means the shareholder base is dominated by retail and non-institutional investors.

Quarter	Promoters	FII	DII	Public
Jun 2025	42.52%	0.95%	0.11%	56.43%
Sep 2025	45.55%	2.58%	0.34%	51.52%
Dec 2025	45.55%	1.48%	0.30%	52.67%
Mar 2026	46.03%	1.01%	0.17%	52.79%
Jun 2026	46.24%	4.17%	0.34%	49.25%

FII holding jumped to 4.17% in June 2026 from 1.01% in March. Promoters also cut pledged shares from 36.13% in September 2025 to 20% by December 2025, a move that reassured investors. In July 2026, the stock moved into the BSE Group A category. Rising FII interest suggests the multibagger healthcare stock is starting to appear on global investor radars.

Key Risks Before Buying This Multibagger Healthcare Stock

The biggest risk is valuation. The stock trades at a PE of approximately 274 against an industry PE of around 35.58, and a price to book ratio near 83. Even strong earnings growth may not keep pace with such a premium if sentiment turns. A multibagger healthcare stock trading at this multiple can fall sharply on a single weak quarter.

Second, the business depends heavily on institutional tenders from global health agencies and governments. Tender allocations can be lumpy, and any cut in donor funding for public health programmes could hurt order flow for the multibagger healthcare stock.

Third, volatility is extreme. The Cupid share price fell from Rs 105.39 to about Rs 68 in early January 2026 before recovering, and it slipped about 21% intraday in August 2026 from the Rs 299 peak. Low institutional ownership can make such swings sharper.

Finally, execution of the new Palava capacity and overseas ventures must go to plan. Delays or cost overruns could force the company to miss its raised guidance, which is already built into the multibagger healthcare stock's price.

Download the Univest iOS App or Univest Android App to track the Cupid share price live

Cupid Share: Analyst View

Market experts broadly agree that the business momentum is strong but caution that the price has run far ahead of fundamentals. In January 2026, technical analysts described the Cupid share as overbought and suggested partial profit booking with a trailing stop loss.

Since then, the company has beaten expectations again and the Cupid share price has more than tripled from its post-bonus levels. Analysts note that the multibagger healthcare stock still has limited formal research coverage, which can widen price swings. The stock now trades just around 6% below its record high.

Cupid Share Price Target

No verified brokerage Cupid share price target is currently available, as the stock has limited formal research coverage. Investors should treat unverified online forecasts with caution.

Without a verified Cupid share price target, key price levels offer a better guide. The record high of Rs 299 acts as near-term resistance, while the Rs 265 zone, where the stock found buyers in August and September, is the nearest support.

Management guidance is the other reference point. If Cupid delivers FY27 net profit of Rs 210 crore to Rs 225 crore, the forward PE would fall to roughly 167 to 179 at the current market value, still well above sector averages. Any fresh Cupid share price target from a brokerage will likely hinge on this execution.

Conclusion

This multibagger healthcare stock has earned its 550% gain through real numbers: profits nearly tripled, guidance was raised repeatedly and new capacity is on the way. The 4:1 bonus in March 2026 did not distort the return, since the figures are adjusted.

The flip side is a valuation that leaves little room for error. Investors tracking the Cupid share price should watch Q2 FY27 results, Palava commissioning and tender flows, and consider staggered entries rather than chasing the multibagger healthcare stock at record levels.

Over the next few quarters, the multibagger healthcare stock will be judged less on its past return and more on whether it can hit Rs 725 crore to Rs 750 crore in revenue this year.

Frequently Asked Questions

Which multibagger healthcare stock rose 550% in 1 year?

Ans. Cupid Ltd (NSE: CUPID) is the multibagger healthcare stock that gained approximately 550.05% over one year as of 10 September 2026. It ranked second among 101 NSE stocks in our screen for 1-year returns.

Why did the Cupid share price rise so much?

Ans. The Cupid share price rose on sharp profit growth, which made it a standout multibagger healthcare stock,, repeated guidance upgrades and new capacity. Q1 FY27 net profit jumped about 194% to Rs 44.15 crore, and FY27 revenue guidance was raised to Rs 725 crore to Rs 750 crore.

Did the Cupid bonus issue affect the 1-year return?

Ans. No. Cupid issued 4:1 bonus shares with a record date of 9 March 2026, but the 550% return is calculated on bonus-adjusted prices. The gain reflects real price appreciation.

What were Cupid Q1 FY27 results?

Ans. Cupid reported Q1 FY27 revenue of Rs 156.99 crore, up about 142% year on year, and net profit of Rs 44.15 crore, up about 194%. The operating margin of the multibagger healthcare stock stood at 40.29%.

What is the 52-week high and low of Cupid?

Ans. Cupid has a 52-week high of Rs 299, hit in August 2026, and a 52-week low of Rs 37.46. The multibagger healthcare stock traded around Rs 281.40 on 10 September 2026.

Is this multibagger healthcare stock overvalued?

Ans. On trailing numbers, yes. The stock trades at a PE of approximately 274 against an industry PE of about 35.58, so investors are pricing in several years of strong growth.

What is the Cupid share price target?

Ans. There is no verified brokerage target at present. Investors can track the Rs 299 record high as resistance and the Rs 265 zone as near-term support.

Should I buy a multibagger healthcare stock after a 550% rally?

Ans. After a 550% move, much of the good news is already in the price, so risk is higher for fresh buyers of this multibagger healthcare stock. Staggered buying, a clear stop loss and advice from a SEBI-registered advisor are sensible steps.